Plasma Cell Tumors of the Head and Neck

1983 ◽  
Vol 92 (3) ◽  
pp. 311-313 ◽  
Author(s):  
John G. Batsakis
Keyword(s):  
Multiple Myeloma ◽  
Head And Neck ◽  
Plasma Cell ◽  
Extramedullary Plasmacytoma ◽  
Plasma Cell Granuloma ◽  
Solitary Plasmacytoma ◽  
Disseminated Disease ◽  
Local Significance

In order of frequency, the plasma cell lesions affecting the head and neck are multiple myeloma, extramedullary plasmacytoma, plasma cell granuloma, and solitary plasmacytoma of bone. All except plasma cell granuloma are neoplastic and they are interrelated. The solitary plasmacytoma of bone is regarded as a form of multiple myeloma. The extramedullary plasmacytoma may be a lesion of local significance only or may terminate in a disseminated disease, myelomatosis, that differs clinically and prognostically from multiple myeloma.

scholarly journals Rare Presentation of Primary Extramedullary Plasmacytoma as Lip Lesion

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
Mali Him ◽  
Maggie Meier ◽  
Vikas Mehta
Keyword(s):  
Multiple Myeloma ◽  
Cell Proliferation ◽  
Plasma Cell ◽  
Light Chain ◽  
Extramedullary Plasmacytoma ◽  
Solitary Plasmacytoma ◽  
Rare Presentation ◽  
Lower Lip ◽  
Light Chain Disease ◽  
Extramedullary Plasmacytomas

Malignant plasma cell proliferation can be presented as part of disseminated disease of multiple myeloma, as solitary plasmacytoma of bone, or in soft tissue as extramedullary plasmacytoma. Extramedullary plasmacytomas represented approximately 3% of all plasma cell proliferation. Approximately 80% of extramedullary plasmacytomas occur in the head and neck region while the other 4% occur in the skin and to a lesser extent in the lip. In this paper, we report a rare case of primary cutaneous plasmacytoma involving the lip in a 65-year-old male. The patient presented with a nonhealing lower lip sore for the past 3 years. Upon further workup, there was no evidence of multiple myeloma or light chain disease. The patient was treated with radiation therapy and his last follow-up revealed no evidence of multiple myeloma or light chain disease.

Osteosclerotic Plasmacytoma of maxillary bone (orbital floor)

1984 ◽  
Vol 98 (9) ◽  
pp. 929-938 ◽  
Author(s):  
Thomas A. Mustone ◽  
Marvin P. Fried ◽  
Max L. Goodman ◽  
James H. Kelly ◽  
Marshall Strome
Keyword(s):  
Multiple Myeloma ◽  
Soft Tissue ◽  
Head And Neck ◽  
Plasma Cell ◽  
Orbital Floor ◽  
Solitary Plasmacytoma ◽  
Osteolytic Lesions ◽  
Maxillary Bone ◽  
Plasma Cell Neoplasms ◽  
Extramedullary Plasmacytomas

AbstractPlasma cell neoplasms have been classified as multiple myeloma, solitary plasmacytoma and extramedullary plasmacytoma. They are usually considered as osteolytic lesions of bone except for the rare occurrence of osteosclerotic lesions. This paper describes the first reported osteosclerotic plasmacytoma of the maxillary bone and orbital floor. The difficulties in establishing a diagnosis and the relationship to other plasma cell neoplasms are discussed.Osteosclerotic plasmacytomas are a rare variant of plasma cell tumors which usually produce osteolytic lesions rather than bony sclerosis. Sixty-eight patients with the osteosclerotic variant have appeared in the world literature, with an overall incidence of about 1 per cent in a large series of plasma cell neoplasms (Dreidger and Pruzanski, 1979). There have been only six previous cases of solitary osteosclerotic plasmacytomas reported (Morley and Schweiger, 1964; Roberts et al., 1974; Rodriguez et al. 1976; Rushton, 1965; Schneinker, 1938; Brigham Medical Review, 1961) involving spine, sternum, or rib. None have previously been reported in the head and neck area.Plasma cell tumors have been classified into multiple myeloma, solitary plasmacytomas of bone, and extramedullary plasmacytomas. Multiple myeloma is a disseminated plasma cell malignancy characterized by the production of homogeneous immunoglobulins (whole or fragments) which appear in the serum and urine. Plasma cell tumors can also occur as solitary plasmacytomas, usually in bone, but also in soft tissue. With time, most solitary plasmacytomas develop disseminated disease with all the characteristics of multiple myeloma (Wiltshaw, 1976). Extramedullary plasmacytomas arise in soft tissue rather than bone, and primarily occur in the head and neck region. Clinically, they remain localized and less frequently develop into disseminated myeloma.

scholarly journals Surgery results in low relapse and progression rates in extramedullary plasmacytoma of the head and neck: A case cohort and review of the literature

2020 ◽  
Vol 12 (2) ◽  
Author(s):  
Matevz Skerget ◽  
Tadej Dovsak ◽  
Gregor Kos ◽  
Samo Zver
Keyword(s):  
Multiple Myeloma ◽  
Local Recurrence ◽  
Head And Neck ◽  
Treatment Option ◽  
Local Control ◽  
Extramedullary Plasmacytoma ◽  
Initial Evaluation ◽  
Review Of The Literature

Extramedullary plasmacytoma of the head and neck is a rare indolent neoplasm. Radiotherapy is often the preferred treatment option with excellent local control and survival. The risk of local recurrence or transformation to multiple myeloma is 10- 30%. In our case-cohort, thorough, sensitive initial evaluation for disseminated clonal disease and the incorporation of surgery led to excellent results with no recurrences or systemic progression.

scholarly journals Pulsatile Midline Solitary Plasmacytoma in the Frontal Head Region-A Case Report”

2016 ◽  
Vol 32 (1) ◽  
pp. 39-42
Author(s):  
Md Atikur Rahman ◽  
Aklaque Hossain Khan ◽  
Kanak Kanti Barua
Keyword(s):  
Multiple Myeloma ◽  
Differential Diagnosis ◽  
Case Report ◽  
Histological Examination ◽  
Plasma Cells ◽  
Extramedullary Plasmacytoma ◽  
Solitary Plasmacytoma ◽  
Rare Entity ◽  
Head Region ◽  
Malignant Plasma Cell

Primary craniocerebral plasmacytomas are uncommon and represent only 0.7 % of all plasmacytomas. In this case solitary plasmacytoma in the midline frontal head region of the skull and discuss the clinical features and prognosis of this tumor. Plasmacytoma can present as multiple myeloma, solitary plasmacytoma of the bone or extramedullary plasmacytoma. Solitary plasmacytoma is a rare entity that composes of malignant plasma cells and involves the bone to form only one or two lesions without evidence of disease dissemination. It accounts for only 4% of malignant plasma cell tumors. 50 years old male was suffering from plasmacytoma in the frontal head region in our case which is pulsatile. On images showed multiple differential diagnosis but after operation histological examination revealed plasmacytoma. Bangladesh Journal of Neuroscience 2016; Vol. 32 (1): 39-42

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1973-1973
Author(s):  
Seema Naik ◽  
Paul J. Shaughnessy ◽  
Behyar Zoghi ◽  
Jose C Cruz ◽  
Carlos Bachier
Keyword(s):  
Multiple Myeloma ◽  
Board Of Directors ◽  
Plasma Cell ◽  
Light Chain ◽  
Disease Recurrence ◽  
Solitary Plasmacytoma ◽  
Advisory Committees ◽  
Autologous Transplants ◽  
Lytic Lesions ◽  
Drug Regimens

Abstract Introduction: Outcomes of Multiple myeloma (MM) have improved in the recent years with combination of novel agents, autologous transplants followed by maintenance therapies. One of the current challenges is to optimize transplant strategies for MM patients with extramedullary plasmacytomas (EMP). Patients and Methods: We retrospectively analyzed outcomes of 237 consecutive MM patients (M132:F105) who underwent ASCT at Texas Transplant Institute, between December 2011 and June 2014. The study was approved by Institutional Review Board. The median length of follow-up was 44.8 months (10 - 86.8 months) in all patients. Censoring date was the last clinic visit prior to December 2014. Results: A total of 237 MM patients were evaluated for presence of plasmacytomas. Patients presented either with multiple intraosseous lytic lesions (MM-IOL) without EMP (n=105; 44%); MM without lytic lesions or EMP in (n=80; 34%) and remaining MM-EMP (n=52; 22%) presented with EMP without multiple lytic lesions. Disease subtype was nonsecretory (5%; n=13), IGA (15%; n=35), IGG (56%; n=133), kappa light chain (16%; n=38) and lambda light chain (8%; n=18) for all 237 patients. (Table 1). Cytogenetics was available in 216 patients (91%) and statistically different among the 3 groups (p=0.05). The sites of EMP included the abdomen, pelvis, chest wall; liver, soft tissue, with sizes ranging from 1.8 cm 10 cm. EMP patients developed recurrent EMP after autologous transplant in 20% (10/52) cases. Fifty percent of patients with recurrent EMP (5/10) died of EMP progression. A total of 140 (59%) patients received triple drug regimens either CyBorD (n=51; 22%) or VRD (n=89; 38%) prior to transplant. Radiation therapy was given to 42 % (n=22/52) patients with EMP and only 4% patients without EMP (n=8 /185). There was no difference in OS and PFS for patients treated with 2 drugs (VD/RD) compared to 3 drug regimens (CyBorD/VRD) for either OS or PFS. Prior solitary plasmacytoma were seen more frequently in 19% patients (n=10/52) who had EMP manifestations prior to transplant. Prior MGUS /smoldering myelomas were seen in 13 % MM-IOL patients. Disease characterisitics (p=0.0515), plasma cell percentage (p=0.0119) and disease recurrence (p=<0.0001) were statistically different for OS for all 237 patients. Disease characteristics (p=0.0751) and recurrence (p=<0.0001) were prognostic for PFS. 3 year probability of OS was 82% (95% CI, 64%- 92%), 84.7% (95% CI, 72%- 92%) and 71.6% (95% CI, 53%- 84%) for patients MM without EMP, MM-IOL and MM-EMP, respectively. Conclusion: Novel therapeutic approaches including proteasome inhibitors and immunomodulatory agents followed by transplant can overcome poor prognosis of MM-EMP patients. Those that do relapse do extremely poorly suggesting need for alternative new therapies. Table 1. Patient Characteristics Variable All patients MM withoutIOL/EMP MM-IOL MM-EMP (M132:F105) (n=237)(100%) (n=80)(34%) (n=105)(44%) (n=52)(22%) Median age P=0.5038 63 (37-79) 62 (40-76) 63 (37-79) 63 (39-77) MM subtype P=0.9589 IGG subtype 133 (56%) 45(56%) 61(58%) 28(23%) IGG kappa 91 (38%) 31(39%) 42(40%) 18(4%) IGG lambda 42 (18%) 14(18%) 19(18%) 9(17%) IGA Subtype 35 (14.7%) 13(16%) 16(15.2%) 6(12%) Kappa LCD 38 (16%) 14(18%) 16(16%) 8 (15%) Lambda LCD 18 (8%) 4(5%) 8(8%) 6(12%) Nonsecretory 13 (6%) 4(5%) 4(4%) 5(10%) Prior Plasma Cell Disorder* P=0.0001 Smoldering MM* 7 (3%) 3(4%) 4(4%) 0(0%) Plasmacytoma* 13 (6%) 1(1%) 2(2%) 10(19%) MGUS* 26 (11%) 13(16%) 9(9%) 4(8%) Cytogenetics P=0.0586 Normal Cytogenetics 84(34%) 41(51%) 25(26%) 27(54%) Mono 13/13 del 22(13%) 10(13%) 20(19%) 6(12%) 17 del 4(2%) 1(1%) 3(3%) 1(2%) Trisomy 11/t(11:14) 8(3%) 6(8%) 3(3%) 6(12%) T(4:14) 5(2%) 2(2.5%) 4(4%) 2(4%) Hyperdiploidy 22(9%) 6(8%) 11(10%) 2(4%) Prior Treatments P=0.1122 CyBorD 51(22%) 19 (24%) 26(25%) 6(12%) VRD/VTD 89(38%) 27(34%) 43(41%) 18(34%) VD/RD/TD 91(38%) 30(38%) 36(34%) 24(46%) Other 6(2.5%) 3(4%) 0(0%) 3(6%) 3 yr OS (p=0.462) 86.1% (65%-95%) 91.3% (81%-96%) 83.4% (65%-93%) 3 yr PFS (p=0.1302) 82.8% (64%-92%) 84.7% (72%-92%) 71.6% (53%-84%) Disclosures Shaughnessy: pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; millenium: Honoraria, Membership on an entity's Board of Directors or advisory committees; sonofi/genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

scholarly journals Head and Neck Solitary Extramedullary Plasmacytoma

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Bijan Khademi ◽  
Zohreh Zandifar ◽  
Mohammad Mohammadianpanah ◽  
Sayed Hasan Hamedi ◽  
Samira Razzaghi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Literature Review ◽  
Head And Neck ◽  
Survival Rates ◽  
Extramedullary Plasmacytoma ◽  
Female Ratio ◽  
Male Female Ratio ◽  
Long Term Follow Up ◽  
Radiotherapy Alone

Introduction. This study aimed to report the characteristics and treatment outcome of 13 patients with solitary extramedullary plasmacytomas of the head and neck and analytical literature review. Materials and Methods. Nine patients (69%) were treated with gross surgical resection followed by radiotherapy, three (23%) were primarily treated with radiotherapy alone, and one (8%) was treated with surgery alone. Results. There were 3 women and 10 men with the median age of 52 years. Nasal cavity (46%) and paranasal sinuses (23%) were the most common primary sites. After a median follow-up of 28 months, 10 patients are alive and free of disease, one is alive with multiple myeloma, and two died of multiple myeloma. In the literature review the median age was 58 years and male/female ratio was 2.7. Sinonasal tract was the most common primary site. Ten-year local control and progression to multiple myeloma rates were 88% and 23%, respectively. The 5- and the 10-year overall survival rates were 71 and 69%, respectively. Conclusion. Radiation therapy with or without surgery is an effective treatment for patients with head and neck extramedullary plasmacytoma. However, long-term follow-up for detection of local recurrence and progression to multiple myeloma is essential.

scholarly journals Extramedullary plasmacytoma of the tongue base: A rare presentation of head and neck plasmacytoma

2013 ◽  
Vol 70 (10) ◽  
pp. 972-975 ◽  
Author(s):  
Jelena Bila ◽  
Bosko Andjelic ◽  
Jelena Bodrozic ◽  
Ljubomir Jakovic ◽  
Maja Perunicic-Jovanovic ◽  
...  
Keyword(s):  
Head And Neck ◽  
Plasma Cell ◽  
Neck Region ◽  
Extramedullary Plasmacytoma ◽  
Tongue Base ◽  
Rare Presentation ◽  
Plasma Cell Disorders ◽  
Plasma Cell Dyscrasias ◽  
Magnetic Resonance Imaging Mri

Introduction. Special entities like solitary bone plasmocytoma (SBP) or extramedullary plasmacytoma (EMP) can be found in a less than 5% of patients with plasma cell disorders. EMP of the tongue represents very rare localization of the head and neck plasmacytoma. Case report. We report a case of 78-years-old woman who developed EMP of the tongue base detected by the magnetic resonance imaging (MRI) of the head and neck region. Immunohistochemical profile of the tumor tissue biopsy (CD38, IgG, kappa positivity) indicated diagnosis of EMP. The diagnosis was established with additional staging which confirmed the absence of other manifestation of the disease. The patient was treated with 40 Gy of radiotherapy in 20 doses resulting in the achievement of the complete remission of the disease. This case was discussed with the reference to the literature. Conclusion. EMP of the tongue base is a very rare entity of plasma cell dyscrasias. Appropriate irradiation results in the achievement of a long-term remission and a potential cure of the disease.

scholarly journals Extramedullary plasmacytoma of the tongue: A case report

2021 ◽  
Vol 2 (6) ◽  
Author(s):  
Leart Berdica ◽  
◽  
Teona Bushati ◽  
Alfred Aga ◽  
Emirjona Vajushi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Differential Diagnosis ◽  
Plasma Cell ◽  
Plasma Cells ◽  
Histopathological Examination ◽  
English Literature ◽  
Extramedullary Plasmacytoma ◽  
Imaging Data ◽  
Plasma Cell Neoplasms ◽  
Extramedullary Plasmocytoma

Background: Tongue extramedullary plasmacytoma is a very rare pathology. Despite rare cases, extramedullary plasmacytoma should be considered as a differential diagnosis in case of a mass in the tongue. A total of 19 cases were reported with EMP in English literature along with the case we will address. It is characterized by a monoclonal neoplastic proliferation of plasma cells in the absence of multiple myeloma (MM). Histopathology and immunohistochemistry are very important for the diagnosis and differential diagnosis. Case presentation: The case we will describe is an 80-year-old lady from Albania who presents with a vegetative lesion in the form of a thick plate on the dorsal part of the tongue with dimensions 6 X 5 X 1.5 cm. A material of 0.5 cm diameter was taken from the lesion for the biopsy. After histopathological examination, immunohistochemical examinations, and after correlations with laboratory, clinical and imaging data, the diagnosis of extramedullary plasmacytoma of the tongue was reached. The patient underwent radiotherapy treatment. Conclusions: EMP is a rare tumor, accounting for 3% of plasma cell neoplasms and <1% of all head and neck tumors. The diagnosis of EMP, in this case, was reached with biopsy, immunohistochemistry, and the correlation with laboratory and imaging data. We will show the importance of biopsy along with immunohistochemistry in the diagnosis and differential diagnosis of extramedullary plasmocytoma of the tongue. Keywords: plasmacytoma; immunohistochemistry; biopsy; plasma cell. Abbreviations: EMP: Extramedullary plasmacytoma; MM: Multiple myeloma; Cm: centimeter

Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias

2010 ◽  
pp. 15-62 ◽  
Author(s):  
Ronald C. Walker ◽  
Laurie Jones-Jackson ◽  
Twyla Bartel ◽  
Tracy Brown ◽  
Bart Barlogie
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Solitary Plasmacytoma ◽  
Plasma Cell Dyscrasias

scholarly journals Solitary Plasmacytoma of The Jaws: Therapeutically Considerations and Prognosis: A Case Report

2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Mohamed Hamdy Helal ◽  
Ahmed Mohamed Bader ◽  
Mohamed A. Fouad ◽  
Malak Yousef Mohamed shoukheba
Keyword(s):  
Soft Tissues ◽  
Plasma Cells ◽  
Malignant Neoplasm ◽  
Neck Region ◽  
Extramedullary Plasmacytoma ◽  
Solitary Plasmacytoma ◽  
Upper Respiratory Tract ◽  
Head And Neck Region ◽  
Plasma Cell Neoplasm ◽  
Disseminated Disease

The plasma cell neoplasm is a rare malignant neoplasm of plasma cells that may present as Extramedullary Plasmacytoma (EMP) in soft tissues especially in the upper respiratory tract, in the bone as a Solitary Plasmacytoma of bone (SPB), or as a part of the multifocal disseminated disease as Multiple Myeloma (MM). The majority of 80% occurs in the head and neck region. In our case, a 23-year-old female patient presented with a non-tender swelling of the gingiva in the upper and lower jaws with the mobility of all teeth. The radiological examination showed severe destruction of bone around all teeth.

Sign in / Sign up

Export Citation Format

Share Document